๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Pharmacokinetics and tissue distribution of a new carbapenem, DA-1131, after intravenous administration to mice, rats, rabbits and dogs

โœ Scribed by So H. Kim; Jong W. Kwon; Myung G. Lee


Publisher
John Wiley and Sons
Year
1998
Tongue
English
Weight
224 KB
Volume
19
Category
Article
ISSN
0142-2782

No coin nor oath required. For personal study only.

โœฆ Synopsis


The pharmacokinetic parameters including tissue distribution and/or biliary excretion of DA-1131, a new carbapenem, were evaluated after intravenous (iv) administration to mice, rats, rabbits, and dogs. After i.v. administration to mice (20, 50, 100, and 200 mg kg-1), rats (50, 100, 200, and 500 mg kg-1), rabbits (20, 50, 100, and 200 mg kg-1), and dogs (10, 20, 50, 100, and 200 mg kg-1), the pharmacokinetic parameters of DA-1131 seemed to be independent of DA-1131 doses studied in all four animal species. However, the renal clearance of percentage of i.v. dose of DA-1131 excreted in 24 h urine as unchanged drug decreased significantly in rabbits (from 200 mg kg-1) and dogs (from 100 mg kg-1) due to reduced kidney function induced by DA-1131. The creatinine clearance decreased significantly in rabbits at 200 mg kg-1 compared with that in the control rabbits (0.466 versus 4.31 mL min-1 kg-1). Renal active secretion of DA-1131 was observed in rabbits and was less considerable in rats, but renal active reabsorption of DA-1131 was observed in dogs. Although DA-1131 was widely distributed in all tissues studied in mice (20-200 mg kg-1), rats (200 mg kg-1), rabbits (50 mg kg-1), and dogs (50 mg kg-1) affinity of DA-1131 for tissues was low: the tissue-to-plasma concentration ratios were greater than unity only in the kidney and/or liver. The low affinity of DA-1131 for tissues was also supported by relatively low values of the apparent volume of distribution at steady state in rats (147-187 mL kg-1), rabbits (91.7-148 mL kg-1), and dogs 243-298 mL kg-1). The contribution of biliary excretion of unchanged DA-1131 to nonrenal clearance of DA-1131 seemed to be minor in rats (200 mg kg-1) and dogs (50 mg kg-1); the percentages of i.v. dose excreted in 8 h bile as unchanged DA-1131 were 1.76 and 2.71% after i.v. administration of the drug to rats and dogs, respectively.


๐Ÿ“œ SIMILAR VOLUMES


Interspecies pharmacokinetic scaling of
โœ So H. Kim; Won B. Kim; Myung G. Lee ๐Ÿ“‚ Article ๐Ÿ“… 1998 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 141 KB ๐Ÿ‘ 2 views

The total body clearance (CI), renal clearance (CIr), and apparent volume of distribution at steady state (Vss) of DA-1131, a new carbapenem, after intravenous (iv) administration of the drug, 50 mg kg-1, to mice, rats, rabbits, and dogs were analysed as a function of species body weight (W) using t

Pharmacokinetics of a new carbapenem, DA
โœ So H. Kim; Won B. Kim; Myung G. Lee ๐Ÿ“‚ Article ๐Ÿ“… 1998 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 153 KB

Because physiological changes occurring in diabetes patients could alter the pharmacokinetics of drugs used to treat the disease, the pharmacokinetics and tissue distribution of DA-1131, a new carbapenem antibiotic, were investigated after 1-min intravenous (iv) administration of the drug, 50 mg kg

Pharmacokinetics and tissue distribution
โœ So H. Kim; Jung S. Lee; Myung G. Lee ๐Ÿ“‚ Article ๐Ÿ“… 2000 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 173 KB

Pharmacokinetic parameters of ipriflavone and its main metabolites, M1 and M5, after intravenous administration of spray-dried ipriflavone, SIP (10, 20, and 30 mg/kg as ipriflavone) and tissue distribution of ipriflavone, M1, and M5 after intravenous administration of SIP (20 mg/kg as ipriflavone) w

Pharmacokinetics of a new reversible pro
โœ Kye S. Han; Yoon G. Kim; Joong K. Yoo; Jong W. Lee; Myung G. Lee ๐Ÿ“‚ Article ๐Ÿ“… 1998 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 175 KB ๐Ÿ‘ 1 views

The pharmacokinetics of YH1885 were evaluated after intravenous (iv) and oral administrations of the drug to rats and dogs. The reason for the low extent of bioavailability (F) of YH1885 after oral administration of the drug to rats and the absorption of the drug from various rat gastrointestinal (G

Pharmacokinetic changes of M1, M2, M3 an
โœ Yun J. Choi; Hee J. Lee; Jong W. Kwon; Won B. Kim; Junnick Yang; Myung G. Lee ๐Ÿ“‚ Article ๐Ÿ“… 1998 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 208 KB ๐Ÿ‘ 2 views

The pharmacokinetics of M1 -M4, the metabolites of a new anthracycline antineoplastic agent, DA-125, were compared after intravenous (IV) administration of DA-125, 15 mg kg -1 , to rats pretreated with enzyme inducers, such as phenobarbital (PBT, n =14) and 3-methylcholanthrene (MCT, n= 15), or enzy